8.55am - 4:00pm
Physical Event | Eastern Time

8:55 am Chair’s Opening Remarks

Developing Cryopreservation Processes to Advance Logisitics

9:00 am Panel: Evaluating Whether the Use of Fresh or Frozen Leukapheresis is More Beneficial

  • Christopher Baldwin Senior Director, Cell & Gene Therapy Supply Chain, GlaxoSmithKline
  • Guanglin Yu Research Assistant, University of Minnesota
  • Kawa Chiu Vice President of CMC, Supply Chain and eSystems, Lyell Immunopharma


• Evaluating the pros and cons of using fresh or frozen Leukapheresis
• Assessing whether the use of fresh Leukapheresis is sustainable as patient numbers grows
• Looking at emerging technologies that have promise in short-term storage of Leukapheresis
• Analyzing the impact of fresh and frozen Leukapheresis on process performance and quality attributes of final product
• Understanding the different responses of cell subsets in Leukapheresis to cryopreservation

10:00 am Where is Cold Chain Innovation Particularly Needed for Emerging Cell Therapies?

  • Chia-Hsing Pi Scientist II, Process Development, BlueRock Therapeutics


• Identifying new technologies to advance the cold chain of cell therapies
• Implementing novel systems in cryogenic storage for securing the self-life of cell products
• Streamlining the cryopreservation process to increase flexibility and robustness
• Establishing best practices for cryopreserving, storing, shipping and thawing of cells

10:30 am Morning refreshments & Networking

Preparing for Future Needs to Achieve Efficient Upscaling

11:30 am Discussion Session: Points to Consider in Moving Through the Development Pipeline

  • David Townson VP Immuno-Oncology and Precision Medicine, Bayer Oncology, Bayer


• Partnership model options
• Development strategy and investment timing – how this shapes the future
• Lessons from recent launches

12:00 pm Ensuring Consistent Supply Procurement Throughout the Upscaling of Cell Therapy

  • Hang Yuan Vice President, Process Development , BlueRock Therapeutics


• Understanding the future supply demands created by growth of cell therapies
• Securing resources to cater for high volumes of individual manufacturing
• Creating a supply ecosystem that allows small and large companies to occupy
the same space

12:30pm Lunch Break & Networking

1:30 pm Preparing a Patient Operations Environment to Cater for Increased Apheresis Demands


• Recognizing the need for staff resource expansion to provide comprehensive
care for patients
• Increasing capacity in advance of increased demand to satisfy individual
customer needs
• Executing a robust scheduling system to manage higher patient numbers whilst
maintaining chain of identity

2:00 pm Expanding Infrastructure to Aid Global Availability of Cell Therapies

  • David Setboun Chief Operating Officer, Brainstorm Cell Therapeutics


• Securing reliable supplies in all locations to prevent inequalities in treatment
• Accepting the need for cryopreservation storage and shipping facilities prior to onboarding novel therapy locations
• Establishing patient center locations with good transport links to simplify
logistical needs

2:30pm Afternoon Refreshments and Networking

Learning from Covid to Secure a Robust Supply Chain Ecosystem in the Future

3:00 pm Panel: Applying Lessons Learned During Covid to Reinforce the Supply Chain


• Preparing for decreases in supply to avoid donor cell waste
• Understanding the implications of shortages to prepare for future logistical challenges
• Appreciating the positive outcomes of Covid and employing consequent risk mitigation plans

3:30 pm Implementing Risk Management Strategies to Enforce Robustness in the Supply Chain

  • Tiffany Clement Cell Therapies Core Inventory Management &, Moffitt Cancer Center


• Keeping up to date with Covid-related changes in country-specific regulations to allow continuous import
• Increasing supply chain flexibility to eliminate dependency on scheduled events
• Learning from Covid-induced challenges to build a strong strategy moving

4:00pm Close of Conference